Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome, Post-COVID Condition
- Main trialPhase 3
- “REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.”In the company’s words, NCT07184385 on ClinicalTrials.gov
Other drugs for Long COVID
- MaravirocHealthBio, Inc. · Phase 2/3
- ApabetaloneResverlogix Corp · Phase 2/3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2
- VYD2311Invivyd, Inc. · Phase 2
- RimonabantSinfatin S.L · Phase 2
- Paragon Novel Metabolic RegulatorParagonClinicals Inc. · Phase 2
Coming up1
- 30 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 30 Jun 2027 | A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition | |
| Phase 2Completed | 26 Jul 2024 | Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026